Send to

Choose Destination
See comment in PubMed Commons below
EuroIntervention. 2011 Oct 30;7(6):723-9. doi: 10.4244/EIJV7I6A115.

The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation.

Author information

  • 1Institute of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.



Many inoperable patients with severe aortic stenosis (AS) are not immediately eligible for transcatheter aortic valve implantation (TAVI). We evaluated the role of percutaneous balloon aortic valvuloplasty (BAV) in this setting.


Among 210 consecutive patients referred to our institution for BAV, we identified three groups: immediately eligible for TAVI (n=65, 31%), excluded from TAVI (n=67, 32%), BAV as a bridge to TAVI (n=78, 37%). This last group comprised patients with low left ventricular ejection fraction, frailty or enfeebled status, symptoms of uncertain origin, critical conditions, moderate-to-severe mitral valve regurgitation, need of major non-cardiac surgery. Outpatient clinic visit and echocardiography were performed around one month after BAV to decide the final therapeutic strategy. Mean age was 81±8 years and the vast majority of patients had comorbidities and high-risk features. The incidence of periprocedural adverse events was 6.4%: 5.1% death (four patients: one procedural complication, three, natural disease progression), 1.3% minor stroke. After BAV, 46% of these patients were deemed eligible for TAVI, and 28% for cardiac surgery. Patients who underwent TAVI after bridge BAV showed 94% 30-day survival.


BAV is a safe and effective tool to bridge selected patients to TAVI when indications are not obvious.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Europa Digital & Publishing
    Loading ...
    Write to the Help Desk